How to Source Tenofovir Disoproxil Fumarate(TDF) tablets for Pharmaceutical Formulation

Tenofovir Disoproxil Fumarate(TDF) tablets (Oral tablets, 300 mg) is classified under Hepatitis. It is therapeutically aligned with reference brands such as Viread® (EU & US). This guide highlights key sourcing factors buyers should consider when procuring high-quality Tenofovir Disoproxil Fumarate(TDF) tablets for formulation, R&D, or bulk manufacturing.

1. Regulatory Compliance & Documentation

Ensure suppliers provide:

• ✔ Valid DMF (Drug Master File)
• ✔ COA (Certificate of Analysis) for each batch
• ✔ GMP, ISO, or ICH Q7 compliance certificates

2. Purity, Grade & Specification Matching

Tenofovir Disoproxil Fumarate(TDF) tablets must meet exact grade and purity for your dosage form:

• ✔ USP / EP / JP grade verification
• ✔ Particle size distribution check
• ✔ Residual solvent and heavy metal limits

3. Supplier Reliability & Audit History

• ✔ Positive past audit reports
• ✔ Pharma client references
• ✔ Years of proven API manufacturing experience

4. Commercial Terms: Pricing, MOQ & Flexibility

• ✔ Transparent pricing
• ✔ Pilot batch MOQ flexibility
• ✔ Volume-based discounts

5. Lead Time, Inventory & Logistics

Typical lead time for Tenofovir Disoproxil Fumarate(TDF) tablets is 4–6 weeks.

• ✔ Emergency dispatch options
• ✔ Regional warehousing
• ✔ Special storage if needed

6. Formulation Support

• ✔ Technical datasheets
• ✔ Sample availability
• ✔ Stability study support

Conclusion

Sourcing Tenofovir Disoproxil Fumarate(TDF) tablets is more than procurement—it’s a strategic partnership. With its oral tablets form and 300 mg specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.

Frequently Asked Questions For Sourcing of Tenofovir Disoproxil Fumarate(TDF) tablets